OncoMatch/Colorectal Cancer (CRC)/PMS2
Colorectal Cancer (CRC)PMS2 Clinical Trials
PMS2 forms a heterodimer with MLH1 in the MMR system; isolated PMS2 loss defines a dMMR/MSI-H tumor eligible for immune checkpoint inhibitors. PMS2 deficiency is the most common Lynch syndrome gene in some populations and can occur as a somatic event. Trials for dMMR CRC include PMS2-deficient patients, who respond to pembrolizumab and combination immunotherapy approaches.
Top recruiting PMS2 Colorectal Cancer (CRC) trials
Ranked by phase and US site count. See all 34 trials matched to your profile →
Comparing Chidamide+Sintilimab+Bev With Standard Second-line FOLFIRI+Bev in Advanced MSS/pMMR mCRC
Sun Yat-sen University
mFOLFOX6 + Bevacizumab + PD-1 Monoclonal Antibody Vs. mFOLFOX6 in Locally Advanced pMMR/MSS CRC
Jun Huang
Neoadjuvant Serplulimab & Bevacizumab With FOLFOX vs. FOLFOX Alone in RAS/BRAF WT, pMMR/MSS CRC Patients
Sun Yat-sen University
Node-sparing Short-Course Radiation Combined With CAPOX and Tislelizumab for MSS Rectal Cancer
Sir Run Run Shaw Hospital
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
Sun Yat-sen University
Node-Sparing Short-Course Radiotherapy Sequential Chemotherapy and PD-1 Inhibitor for Mid/Low pMMR/MSS Rectal Cancer (MODIFI-RC-II)
Sixth Affiliated Hospital, Sun Yat-sen University
Browse other molecular targets with active Colorectal Cancer (CRC) trials.